Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, Seoane J, Reis-Filho JS. De Mattos-Arruda L, et al. Among authors: nuciforo p. Mol Oncol. 2014 Feb;8(1):150-8. doi: 10.1016/j.molonc.2013.10.006. Epub 2013 Oct 31. Mol Oncol. 2014. PMID: 24220311 Free PMC article.
Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.
Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, Parra JL, De Mattos-Arruda L, Grueso J, Hernández-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J, Baselga J. Serra V, et al. Among authors: nuciforo p. Cancer Discov. 2013 Nov;3(11):1238-44. doi: 10.1158/2159-8290.CD-13-0132. Epub 2013 Aug 15. Cancer Discov. 2013. PMID: 23950206
Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.
Parra-Palau JL, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, Zacarias-Fluck M, Pedersen K, Pandiella A, Nuciforo P, Serra V, Cortés J, Baselga J, Perou CM, Prat A, Rubio IT, Arribas J. Parra-Palau JL, et al. Among authors: nuciforo p. J Natl Cancer Inst. 2014 Sep 24;106(11):dju291. doi: 10.1093/jnci/dju291. Print 2014 Nov. J Natl Cancer Inst. 2014. PMID: 25253614 Free PMC article.
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart M, Baselga J. Scaltriti M, et al. Among authors: nuciforo p. Clin Cancer Res. 2015 Feb 1;21(3):569-76. doi: 10.1158/1078-0432.CCR-14-1824. Epub 2014 Dec 2. Clin Cancer Res. 2015. PMID: 25467182
Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.
Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortés J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. Vicario R, et al. Among authors: nuciforo p. PLoS One. 2015 Jun 15;10(6):e0129876. doi: 10.1371/journal.pone.0129876. eCollection 2015. PLoS One. 2015. PMID: 26075403 Free PMC article.
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.
Prat A, Galván P, Jimenez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, Álvarez M, Díaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ramón Y Cajal S, Peg V, Alba E. Prat A, et al. Among authors: nuciforo p. Clin Cancer Res. 2016 Feb 1;22(3):560-6. doi: 10.1158/1078-0432.CCR-15-0630. Epub 2015 Jul 7. Clin Cancer Res. 2016. PMID: 26152740 Free article.
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.
Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M. Nuciforo P, et al. Mol Oncol. 2016 Jan;10(1):138-147. doi: 10.1016/j.molonc.2015.09.002. Epub 2015 Sep 15. Mol Oncol. 2016. PMID: 26422389 Free PMC article.
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L. De Mattos-Arruda L, et al. Oncotarget. 2015 Nov 10;6(35):37269-80. doi: 10.18632/oncotarget.5495. Oncotarget. 2015. PMID: 26452030 Free PMC article.
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G. Hergueta-Redondo M, et al. Oncotarget. 2016 Aug 30;7(35):56295-56308. doi: 10.18632/oncotarget.10787. Oncotarget. 2016. PMID: 27462779 Free PMC article.
181 results